<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230697</url>
  </required_header>
  <id_info>
    <org_study_id>662010</org_study_id>
    <nct_id>NCT01230697</nct_id>
  </id_info>
  <brief_title>Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)</brief_title>
  <acronym>SORHORM</acronym>
  <official_title>Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib. Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study includes the recruitment of patients with advanced renal cells carcinoma and
      hepatocarcinoma in treatment with sorafenib. Multicenter cohort study. It is a prospective
      observational study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several tyrosin kinase inhibitors are able to induce hypophosphatemia but the mechanisms
      underling this metabolic disorder are unknown.

      Sorafenib is probably the drug in which this metabolic disturbance is most frequent. The aim
      of the study is identify variation of blood serum analites involved in hypophosphatemia in
      patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with sorafenib.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the value variations of hormones involved in phosphate homeostasis during sorafenib administration</measure>
    <time_frame>one year</time_frame>
    <description>Assess the effects of sorafenib hormones involved in phosphate homeostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify metabolic differences between renal cells cancer and hepatocarcinoma</measure>
    <time_frame>one year</time_frame>
    <description>identify differences in phosphate hormone behavior between renal cells cancer and hepatocarcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify variations on bone mass during sorafenib treatment</measure>
    <time_frame>one year</time_frame>
    <description>Assess Sorafenib effects on bone density and the relationship with phosphate related hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify correlations between phosphate related hormones and side effects during sorafenib treatment as a Measure of safety and tolerability</measure>
    <time_frame>one year</time_frame>
    <description>Identify the relationship between phpsphate hormones variation and Sorafenib side effects (e.g.asthenia, blood hypertension, skin toxicity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify correlations between phosphate related hormones variations and patients outcome (TTP and overall survival)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Sofanenib and Hypophosphatemia</arm_group_label>
    <description>Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 800mg/die oral</description>
    <arm_group_label>Sofanenib and Hypophosphatemia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum analites involved in phosphate homeostasis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced renal cells carcinoma and hepatocarcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age over 18 years

          2. Histologically documented kidney cancer or hepatocarcinoma

          3. Performance status more than / equal to 2

          4. Life expectancy &gt; 12 weeks

          5. in patients with recent surgery, the wound should be completely healed before taking
             Sorafenib

          6. required initial laboratory values: absolute neutrophil count &gt; 1500/ul Platelets &gt;
             100,000/ul., Hemoglobin &gt; 9.0 g/dl, Creatinine, SGOT, SGPT less than 2.0 X upper limit
             of normal Bilirubin less than/equal to upper limit of normal(ULN)

          7. Appropriate patienty compliance

        Exclusion Criteria:

          1. myocardial infarction or significant change in anginal pattern within the last 6
             months, symptomatic congestive heart failure (NYHA Class III or higher) or
             uncontrolled cardiac arrhythmia,

          2. previous history of malignant disease with the exception of non melanoma skin cancer
             curatively treated,

          3. significant neurologic or psychiatric diseases preventing patients to give a valid
             informed consent

          4. Sintomatic brain metastases

          5. because patients with immune deficiency are at increased risk of lethal infections
             when treated with marrow-suppressive therapy, HIV-positive patients receiving
             combination anti-retroviral therapy are excluded

          6. patients with seizures that need medical treatment

          7. History of heterologous transplantation

          8. Patients with previous or active bleeding

          9. Dialysis patients

         10. Patients with history of primary hyperparathyroidism

         11. Dysphagic patients

         12. Taking more than four weeks of entry into the study of other bio-chemotherapy
             treatments

         13. Previous treatment with Sorafenib

         14. Recent (&lt;6 months)or concomitant treatment with biphosphonate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alfredo Berruti</name>
      <address>
        <city>Orbassano (To)</city>
        <state>Turin</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Bellini, MD</last_name>
      <phone>(+39) 011 9026</phone>
      <phone_ext>526</phone_ext>
      <email>elisa.bellini3@tin.it</email>
    </contact>
    <investigator>
      <last_name>Alfredo Berruti, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabella Chiappino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cinzia Ortega, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Pirisi, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonino Picciotto, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camillo Porta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Pia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Bianco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>October 28, 2010</last_update_submitted>
  <last_update_submitted_qc>October 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alfredo Berruti</name_title>
    <organization>Dipartimento di Scienze Cliniche e Biologiche - Università di Torino</organization>
  </responsible_party>
  <keyword>Advanced</keyword>
  <keyword>hepatocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

